Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03471624 · ClinicalTrials.gov registry record · Phase 4
Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)
A Phase 4 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 4
- Development phase
- 270
- Enrollment target
NCT03471624: Completed Phase 4 study, sponsored by Stanford University.
NCT03471624 is a Phase 4 study that has completed, run by Stanford University. The registered enrollment target is 270 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03471624, a Phase 4 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 270 participants
- Enrollment target
Study Summary
Primary Objective: To describe rate of persistence and/or improvement of viral suppression with TAF as with previous anti-HBV (hepatitis B virus) treatment
Primary Outcome
To describe rate of persistence and/or improvement of viral suppression with TAF as with previous anti-HBV treatment.
Interventions
- DRUG Tenofovir Alafenamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2022-04-19 |
| Phase | Phase 4 |
What the finished NCT03471624 record still lists
NCT03471624 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 1 intervention - of which Tenofovir Alafenamide is the first listed.
NCT03471624 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03471624 about?
NCT03471624 is a clinical study titled "Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)". Primary Objective: To describe rate of persistence and/or improvement of viral suppression with TAF as with previous anti-HBV (hepatitis B virus) treatment
What is the current status of trial NCT03471624?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 270 participants. The study started on 2018-05-01. Estimated completion is 2022-04-19.
What interventions are being tested in trial NCT03471624?
The interventions under investigation include: Tenofovir Alafenamide (DRUG).
Who is sponsoring clinical trial NCT03471624?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03471624's enrollment target sits among peer trials
270 318th of 2000 higher than 1,682 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- NCT04372485 · 270 participants · NA
Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents
- NCT04528446 · 270 participants
The Impact of Glomerular Disorders on Bone Quality and Strength
- NCT05215327 · 270 participants · Phase 2
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI